Morsink, Nino Chiron;
Nijsen, Johannes Frank Wilhelmus;
Grinwis, Guillaume Cornelis Maria;
Hesselink, Jan Willem;
Kirpensteijn, Jolle;
van Nimwegen, Sebastiaan Alexander
Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs
Beteiligte:
Morsink, Nino Chiron;
Nijsen, Johannes Frank Wilhelmus;
Grinwis, Guillaume Cornelis Maria;
Hesselink, Jan Willem;
Kirpensteijn, Jolle;
van Nimwegen, Sebastiaan Alexander
Beschreibung:
<jats:sec><jats:title>Introduction</jats:title><jats:p>Minimally invasive microbrachytherapy is in development to treat solid tumors by intratumoral injection of (radioactive) holmium-166 (<jats:sup>166</jats:sup>Ho) microspheres (MS). A high local dose can be administered with minimal damage to surrounding tissue because of the short soft tissue penetration depth of <jats:sup>166</jats:sup>Ho beta radiation. We aimed to prospectively evaluate the safety and efficacy of <jats:sup>166</jats:sup>Ho microbrachytherapy in client-owned canine patients with soft tissue sarcomas (STS).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We included seven dogs with STS not suitable for local excision due to tumor size and/or location. <jats:sup>166</jats:sup>HoMS were suspended in a carrier fluid and multiple needle-injections were performed in predetermined tumor segments to maximize tumor coverage. Tumor response was evaluated using 3D caliper and CT measurements. Follow-up further included monitoring for potential side effects and registration of subsequent treatments and survival, until at least two years after treatment.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Delivered radioactive doses ranged from 70 to 969 Gy resulting in a mean tumor volume reduction of 49.0 ± 21.3% after 33 ± 25 days. Treatment-related side effects consisted of local necrosis (<jats:italic>n</jats:italic> = 1) and ulceration of the skin covering the tumor (<jats:italic>n</jats:italic> = 1), which resolved with basic wound care, and surgical excision of residual tumor, respectively. Residual tumor was surgically resected in six patients after 22–93 days. After a mean follow-up of 1,005 days, four patients were alive, two patients were euthanized because of unrelated causes, and one patient was euthanized because of disease progression after the owner(s) declined subsequent surgical treatment.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p><jats:sup>166</jats:sup>Ho microbrachytherapy was a safe and effective neoadjuvant treatment option for canine patients with STS.</jats:p></jats:sec>